Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 13% Improvement Relative Risk ICU admission 16% Hospitalization time 25% c19colchicine.com Karakaş et al. Colchicine for COVID-19 LATE TREATMENT Favors colchicine Favors control
Karakaş, 336 patient colchicine late treatment study: 13% lower mortality [p=0.72], 16% lower ICU admission [p=0.5], and 25% shorter hospitalization [p=0.0001] https://c19p.org/karakas
copied to clipboard
Reducing length of hospital stay with colchicine
Karakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
31 Jan 2022    Source   PDF   Share   Tweet
Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with higher dosage (1mg/day vs 0.5mg/day). More control patients were on oxygen at baseline (65% vs. 54%).
risk of death, 12.7% lower, RR 0.87, p = 0.72, treatment 16 of 165 (9.7%), control 19 of 171 (11.1%), NNT 71.
risk of ICU admission, 16.0% lower, RR 0.84, p = 0.50, treatment 30 of 165 (18.2%), control 37 of 171 (21.6%), NNT 29.
hospitalization time, 25.0% lower, relative time 0.75, p < 0.001, treatment 165, control 171.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
Karakaş et al., 31 Jan 2022, retrospective, Turkey, peer-reviewed, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit